Antimicrobials — MCQs
On this page
A tourist with a travel history to India presents with complaints of abdominal pain and multiple episodes of watery diarrhea. He reports having food at a local restaurant the previous night. Which of the following antidiarrheal agents is used in this condition?
A patient from a North-Eastern state was diagnosed to have an infection with P. Falciparum malaria. What is the most appropriate treatment for this patient?
Which of the following chelating agents is indicated in iron overdose?
An 18-year-old boy from Rajasthan weighing 50 kg is diagnosed with mixed P . vivax and P . falciparum malaria. What is the appropriate treatment regimen on day 2?
In which phase of clinical trials is drug dosing typically determined?
Which of the following statements about Ciclesonide is incorrect?
Which of the following drugs, when given with erythromycin, can cause QT prolongation and Torsades de Pointes?
Which of the following is an inclusion criterion for the shorter bedaquiline regimen in the treatment of tuberculosis?
Aprepitant is a drug used in the treatment of some cases of chemotherapy-induced nausea and vomiting. What is the mechanism of action of this drug?
Methotrexate use causes reduced synthesis of which of the following?
Antimicrobials US Medical PG Practice Questions and MCQs
Question 1: A tourist with a travel history to India presents with complaints of abdominal pain and multiple episodes of watery diarrhea. He reports having food at a local restaurant the previous night. Which of the following antidiarrheal agents is used in this condition?
- A. Bismuth subsalicylate
- B. Octreotide
- C. Loperamide
- D. Rifaximin (Correct Answer)
- E. Ciprofloxacin
Explanation: ***Rifaximin*** - This patient's symptoms, including **abdominal pain**, **watery diarrhea**, and a recent **travel history to India** coupled with eating at a local restaurant, strongly suggest **traveler's diarrhea**, often caused by bacterial pathogens. - **Rifaximin** is a non-absorbable antibiotic specifically approved for treating non-invasive traveler's diarrhea, as it targets causative bacteria in the gut lumen with minimal systemic absorption. - Rifaximin is preferred due to its **excellent safety profile**, minimal systemic effects, and targeted action against enteric pathogens. *Ciprofloxacin* - **Ciprofloxacin** is a fluoroquinolone antibiotic that can be effective for traveler's diarrhea and has been used historically for this indication. - However, rifaximin is now preferred over ciprofloxacin due to increasing **fluoroquinolone resistance** among enteric pathogens, systemic absorption leading to more side effects, and FDA warnings about serious adverse effects associated with fluoroquinolones. - Ciprofloxacin may be reserved for more severe or invasive diarrhea cases. *Bismuth subsalicylate* - While **bismuth subsalicylate** can be used for symptomatic relief in traveler's diarrhea due to its anti-secretory and anti-inflammatory properties, it is not an antimicrobial agent. - It works by reducing fluid secretion and inflammation but does not directly address the underlying bacterial infection to the same extent as rifaximin. *Octreotide* - **Octreotide** is a somatostatin analog primarily used to treat severe, refractory diarrhea associated with conditions like neuroendocrine tumors or chemotherapy, not typical bacterial traveler's diarrhea. - Its mechanism involves inhibiting gastrointestinal hormone secretion and reducing intestinal motility, which is too potent for this common, self-limiting condition. *Loperamide* - **Loperamide** is an opioid-receptor agonist that acts as an anti-motility agent, reducing the frequency of bowel movements. - It is generally contraindicated as a primary treatment for traveler's diarrhea when an invasive bacterial infection is suspected, as it can prolong the retention of toxins and pathogens in the gut.
Question 2: A patient from a North-Eastern state was diagnosed to have an infection with P. Falciparum malaria. What is the most appropriate treatment for this patient?
- A. Chloroquine
- B. Mefloquine
- C. Sulfadoxine plus pyrimethamine
- D. Artemether plus lumefantrine (Correct Answer)
- E. Quinine plus doxycycline
Explanation: ***Artemether plus lumefantrine*** - Artemether-lumefantrine is the recommended first-line treatment for **uncomplicated P. falciparum malaria** in regions with known **chloroquine resistance**, such as North-Eastern India. - This combination therapy, an **Artemisinin-based Combination Therapy (ACT)**, is highly effective due to its rapid parasiticidal action and synergy. *Chloroquine* - Chloroquine resistance in **P. falciparum malaria** is widespread, particularly in many parts of India, including the North East. - Using chloroquine alone would likely lead to **treatment failure** and worsening of the patient's condition. *Mefloquine* - Mefloquine is an alternative treatment option, but it has significant drawbacks including **neuropsychiatric side effects** (e.g., anxiety, depression, hallucinations) and a long half-life. - It is often reserved for specific situations or as a second-line agent when ACTs are not available or contraindicated. *Sulfadoxine plus pyrimethamine* - **Sulfadoxine-pyrimethamine (SP)** is an older antimalarial drug combination that is not recommended as first-line treatment for **uncomplicated P. falciparum malaria** due to widespread **parasite resistance**. - While it was formerly used for prophylaxis and intermittent presumptive treatment, its efficacy against P. falciparum has significantly declined. *Quinine plus doxycycline* - **Quinine plus doxycycline** is an effective alternative for treating **P. falciparum malaria**, particularly in **severe cases** or when ACTs are contraindicated or unavailable. - However, it is **not the first-line treatment** for uncomplicated malaria due to longer treatment duration (7 days), more frequent dosing, and potential side effects (cinchonism, GI disturbances). - Requires adherence to a multi-day regimen, making ACTs more practical for uncomplicated cases.
Question 3: Which of the following chelating agents is indicated in iron overdose?
- A. Desferrioxamine (Correct Answer)
- B. BAL
- C. Calcium Edetate
- D. DTPA
- E. Penicillamine
Explanation: ***Desferrioxamine*** - **Desferrioxamine** is a **chelate** formed by the bacterium *Streptomyces pilosus* that has a high affinity for **iron**. - It is currently the most commonly used chelating agent for **acute iron overdose** and **chronic iron overload** conditions like hemochromatosis or transfusional hemosiderosis. *BAL* - **BAL (dimercaprol)** is a chelating agent primarily used for poisoning with **arsenic**, **mercury**, and **gold**. - It works by forming stable cyclic compounds with these metals, facilitating their excretion. *Calcium Edetate* - **Calcium edetate (Calcium-EDTA)** is primarily used for **lead poisoning**. - It works by forming a stable, water-soluble complex with lead, which is then excreted by the kidneys. *DTPA* - **Diethylenetriamine pentaacetate (DTPA)** is a chelating agent primarily used for poisoning with **plutonium** and other **radioactive metals**. - It is not indicated for iron overdose. *Penicillamine* - **Penicillamine** is a chelating agent primarily used for **copper** overload (Wilson's disease) and can also be used for **lead** and **mercury** poisoning. - It is not effective for iron chelation in overdose situations.
Question 4: An 18-year-old boy from Rajasthan weighing 50 kg is diagnosed with mixed P . vivax and P . falciparum malaria. What is the appropriate treatment regimen on day 2?
- A. Artesunate 50 mg (4 tablets) + Primaquine 2.5 mg ( 6 tablets)
- B. Artesunate 50 mg (4 tablets) + Primaquine 7.5 mg (6 tablets)
- C. Artesunate 50 mg (4 tablets) + Sulfadoxine/ pyrimethamine ( 750/37.5 mg ) (2 tablets) + Primaquine 2.5 mg ( 6 tablets) (Correct Answer)
- D. Artesunate 50 mg (4 tablets) + Sulfadoxine/ pyrimethamine ( 750/37.5 mg ) (2 tablets) + Primaquine 7.5 mg ( 6 tablets)
- E. Artesunate 50 mg (4 tablets) only
Explanation: ***Artesunate 50 mg (4 tablets) + Sulfadoxine/pyrimethamine (750/37.5 mg) (2 tablets) + Primaquine 2.5 mg (6 tablets)*** - For **mixed P. vivax and P. falciparum malaria**, the standard treatment regimen in India includes **Artesunate, Sulfadoxine/Pyrimethamine (SP)**, and **Primaquine**. - **Artesunate** and **SP** target the erythrocytic stages of P. falciparum, while **Primaquine** is essential for killing P. vivax hypnozoites (to prevent relapse) and P. falciparum gametocytes (to reduce transmission). - On **Day 2**, the patient continues with Artesunate along with SP (if given as single dose on Day 0, this would not be repeated; if following a specific protocol where Day 2 includes all three drugs, this represents the complete regimen). - The dosage of Primaquine of **2.5 mg** (0.25 mg/kg for 50 kg individual) daily for 14 days is appropriate for P. vivax radical cure. *Artesunate 50 mg (4 tablets) + Primaquine 2.5 mg (6 tablets)* - This regimen is incomplete for **mixed infections** as it lacks **Sulfadoxine/Pyrimethamine (SP)**, which is crucial for effective treatment of P. falciparum infections. - While Primaquine is included, the absence of SP would likely lead to treatment failure or recrudescence of **P. falciparum**. *Artesunate 50 mg (4 tablets) + Primaquine 7.5 mg (6 tablets)* - This regimen also omits **Sulfadoxine/Pyrimethamine (SP)**, which is necessary for the treatment of P. falciparum in mixed infections. - The **Primaquine dosage of 7.5 mg** is higher than typically used for P. vivax radical cure in this context (usually 0.25 mg/kg), and the absence of SP makes this regimen inadequate for mixed malaria. *Artesunate 50 mg (4 tablets) + Sulfadoxine/pyrimethamine (750/37.5 mg) (2 tablets) + Primaquine 7.5 mg (6 tablets)* - While this option includes **Artesunate** and **SP** for P. falciparum, the **Primaquine dose of 7.5 mg** is too high for the standard daily dose required for P. vivax radical cure in a 50 kg individual (which is 2.5 mg/day). - An inappropriately high dose of Primaquine for daily use for 14 days increases the risk of side effects, especially in individuals with **G6PD deficiency**, and is not the recommended regimen for mixed malaria in India. *Artesunate 50 mg (4 tablets) only* - While Artesunate is a key component of treatment, using it **alone on Day 2** without SP is inadequate for **P. falciparum** and does not address **P. vivax hypnozoites**. - This incomplete regimen would not provide radical cure for P. vivax and lacks the partner drug (SP) necessary for effective clearance of P. falciparum parasites.
Question 5: In which phase of clinical trials is drug dosing typically determined?
- A. Phase 1 (Correct Answer)
- B. Phase 2
- C. Phase 3
- D. Phase 4
- E. Phase 0
Explanation: ***Phase 1*** - This phase involves a small group of **healthy volunteers** to assess the drug's safety, **pharmacokinetics (PK)**, and establish an initial dosing range. - The primary goal is to determine a **safe dosage level**, establish the **maximum tolerated dose (MTD)**, and identify potential side effects. - This is where drug dosing is **typically determined**. *Phase 0* - This is an exploratory phase involving **microdosing** studies with subtherapeutic doses. - The goal is to gather preliminary PK/PD data, but **not to determine therapeutic dosing**. *Phase 2* - This phase involves a larger group of **patients** with the condition to be treated. - The main goal is to evaluate the drug's **effectiveness** and further assess safety, but not primarily to determine initial dosing. *Phase 3* - This phase involves a large number of patients across multiple sites to confirm the drug's **efficacy** and monitor side effects in a broader population. - Dosing strategies have generally been established in earlier phases, and this phase primarily validates them. *Phase 4* - This phase occurs **after a drug has been approved** and marketed. - It involves ongoing surveillance to monitor long-term effects, collect additional information on safety, and identify new uses, but not initial dose determination.
Question 6: Which of the following statements about Ciclesonide is incorrect?
- A. Oral candidiasis is common with its use. (Correct Answer)
- B. It is a prodrug activated by bronchial esterase.
- C. It has comparable efficacy to other inhalational corticosteroids.
- D. It has fewer side effects than other inhalational corticosteroids.
- E. It has low systemic bioavailability due to extensive first-pass metabolism.
Explanation: ***Oral candidiasis is common with its use.*** * Ciclesonide is a **prodrug** that is activated in the lungs, which minimizes systemic exposure and reduces the risk of local side effects like **oral candidiasis**. * Therefore, oral candidiasis is **less common** with ciclesonide compared to other inhaled corticosteroids that deliver the active drug directly to the oral cavity. *It is a prodrug activated by bronchial esterase.* * Ciclesonide is indeed a **prodrug** that is converted into its active metabolite, **des-ciclesonide**, by **esterases** primarily found in the lungs. * This specific activation mechanism helps ensure that the drug's therapeutic effects are localized to the airways while minimizing systemic exposure. *It has comparable efficacy to other inhalational corticosteroids.* * Studies have shown that ciclesonide provides **comparable efficacy** to other established inhaled corticosteroids in controlling asthma symptoms and improving lung function. * Its potent anti-inflammatory effects are effective in reducing airway hyperresponsiveness and inflammation. *It has fewer side effects than other inhalational corticosteroids.* * Because ciclesonide is a prodrug activated in the lungs and has a **high protein binding capacity**, it has a reduced likelihood of systemic side effects. * This contributes to a **favorable safety profile**, with a lower incidence of both local and systemic adverse drug reactions compared to some other inhaled corticosteroids. *It has low systemic bioavailability due to extensive first-pass metabolism.* * Ciclesonide has **very low systemic bioavailability** (<1%) when administered via inhalation. * The active metabolite des-ciclesonide that does reach systemic circulation undergoes **extensive first-pass metabolism** in the liver, further reducing systemic exposure. * This pharmacokinetic property contributes to its excellent safety profile and minimal systemic adverse effects.
Question 7: Which of the following drugs, when given with erythromycin, can cause QT prolongation and Torsades de Pointes?
- A. Astemizole (Correct Answer)
- B. Cetirizine
- C. Loratadine
- D. Promethazine
- E. Fexofenadine
Explanation: ***Astemizole*** - **Astemizole** is a second-generation antihistamine that undergoes extensive metabolism by the **CYP3A4 enzyme**. - Concomitant use with **erythromycin**, a potent **CYP3A4 inhibitor**, significantly increases astemizole plasma concentrations, leading to **QT prolongation** and an elevated risk of **Torsades de Pointes**. *Cetirizine* - **Cetirizine** is another second-generation antihistamine that is primarily eliminated via **renal excretion** and does not undergo significant CYP450 metabolism. - Therefore, its co-administration with **erythromycin** does not typically lead to clinically significant drug interactions impacting cardiac repolarization. *Fexofenadine* - **Fexofenadine** is a second-generation antihistamine and active metabolite of terfenadine that is primarily eliminated via **biliary excretion** and has minimal hepatic metabolism. - While it is a substrate of **P-glycoprotein** (which can be inhibited by erythromycin), fexofenadine has a much safer cardiac profile and does not typically cause **QT prolongation** even with CYP3A4 inhibitors. *Loratadine* - **Loratadine** is a second-generation antihistamine that is metabolized by **CYP2D6** and **CYP3A4**, but its active metabolite, desloratadine, has a lower propensity for QT prolongation. - While erythromycin is a CYP3A4 inhibitor, the risk of **QT prolongation** with **loratadine** is generally considered much lower than with astemizole, even with concurrent use. *Promethazine* - **Promethazine** is a first-generation antihistamine and phenothiazine derivative that primarily acts as a **dopamine D2 receptor antagonist**. - While it can cause **QT prolongation** on its own at high doses, its metabolism is complex and not predominantly dependent on **CYP3A4** to the extent that interaction with **erythromycin** poses the same severe risk as with astemizole.
Question 8: Which of the following is an inclusion criterion for the shorter bedaquiline regimen in the treatment of tuberculosis?
- A. Extrapulmonary TB like Tubercular meningitis
- B. Rifampicin resistance with both KatG and inhA mutation
- C. Rifampicin-sensitive TB
- D. Rifampicin-resistant but fluoroquinolone-sensitive TB (Correct Answer)
- E. Extensively drug-resistant TB (XDR-TB)
Explanation: ***Rifampicin-resistant but fluoroquinolone-sensitive TB*** - The **shorter bedaquiline regimen** is specifically recommended for patients with **rifampicin-resistant tuberculosis** who are also sensitive to fluoroquinolones. - This regimen optimizes treatment outcomes by leveraging the effectiveness of both bedaquiline and a potent fluoroquinolone against sensitive strains. *Extrapulmonary TB like Tubercular meningitis* - The shorter bedaquiline regimen is generally not recommended for severe forms of **extrapulmonary TB**, especially those involving the **central nervous system**, due to concerns about drug penetration and efficacy. - These cases often require longer, individualized regimens with stronger central nervous system penetration. *Rifampicin resistance with both KatG and inhA mutation* - The presence of both **KatG** and **inhA mutations** indicates high-level **isoniazid resistance**, which is not the primary criterion for selecting the shorter bedaquiline regimen. - While these mutations are important for guiding isoniazid use, the core inclusion for this regimen is **rifampicin resistance** and **fluoroquinolone sensitivity**. *Rifampicin-sensitive TB* - Patients with **rifampicin-sensitive TB** are usually treated with standard first-line regimens that do not include bedaquiline, as their disease is susceptible to more conventional therapies. - The shorter bedaquiline regimen is reserved for drug-resistant cases, particularly those with rifampicin resistance. *Extensively drug-resistant TB (XDR-TB)* - While **XDR-TB** patients may receive bedaquiline, they typically require **longer, individualized regimens** rather than the shorter standardized regimen. - The shorter bedaquiline regimen is primarily indicated for **rifampicin-resistant TB** that is **fluoroquinolone-sensitive**, whereas XDR-TB involves resistance to both fluoroquinolones and injectable agents, requiring more complex treatment approaches.
Question 9: Aprepitant is a drug used in the treatment of some cases of chemotherapy-induced nausea and vomiting. What is the mechanism of action of this drug?
- A. NK1 antagonist (Correct Answer)
- B. NK3 antagonist
- C. NK1 agonist
- D. NK2 agonist
- E. NK2 antagonist
Explanation: ***NK1 antagonist*** - **Aprepitant** is a selective, high-affinity antagonist of the **neurokinin 1 (NK1) receptor**, which is activated by **substance P**. - By blocking NK1 receptors in the brainstem's **vomiting center**, aprepitant prevents nausea and vomiting, especially in chemotherapy-induced cases. - Aprepitant is particularly effective for **acute and delayed** chemotherapy-induced nausea and vomiting (CINV). *NK3 antagonist* - While **neurokinin 3 (NK3) receptors** are present in the central nervous system, their specific role in chemotherapy-induced nausea and vomiting is less prominent. - Aprepitant does not primarily target NK3 receptors; its antiemetic action is mediated through NK1 blockade. *NK1 agonist* - An **NK1 agonist** would activate the NK1 receptor, potentially *inducing* nausea and vomiting, which is the opposite of the desired therapeutic effect of aprepitant. - Agonists are typically used to stimulate a receptor, not block it as is done with aprepitant. *NK2 antagonist* - **Neurokinin 2 (NK2) receptors** are also part of the tachykinin receptor family, but they are not the primary target for antiemetic drugs like aprepitant. - While NK2 receptors play roles in smooth muscle contraction and inflammation, blocking them is not the mechanism by which aprepitant prevents nausea and vomiting. - Aprepitant's antiemetic efficacy is specifically due to **NK1 receptor antagonism**. *NK2 agonist* - **Neurokinin 2 (NK2) receptors** are also part of the tachykinin receptor family, but they are not the primary target for antiemetic drugs like aprepitant. - Activating NK2 receptors would not provide the antiemetic effect seen with aprepitant, as NK1 receptor antagonism is crucial.
Question 10: Methotrexate use causes reduced synthesis of which of the following?
- A. TMP (Correct Answer)
- B. CMP
- C. GMP
- D. AMP
- E. UMP
Explanation: ***TMP (Thymidylate)*** - Methotrexate is a **folate analog** that inhibits **dihydrofolate reductase (DHFR)**, preventing the regeneration of tetrahydrofolate (THF) from dihydrofolate. - **Tetrahydrofolate** is essential for **thymidylate synthase**, which converts dUMP to **TMP (thymidylate)** - this is the **most directly and significantly affected** nucleotide synthesis pathway. - Reduced TMP synthesis leads to impaired DNA synthesis and is the **primary mechanism** of methotrexate's cytotoxic effects. *CMP (Cytidine monophosphate)* - CMP synthesis occurs via the **de novo pyrimidine pathway** starting from carbamoyl phosphate and aspartate, forming UMP, which is then converted to CMP. - This pathway **does not require tetrahydrofolate** cofactors, so methotrexate does not significantly affect CMP synthesis directly. *GMP (Guanosine monophosphate)* - GMP is a purine nucleotide whose synthesis **does require tetrahydrofolate** derivatives (N10-formyl-THF) at two steps in the de novo purine pathway. - However, the effect on GMP is **less direct and less pronounced** than on TMP synthesis, and cells can partially compensate through salvage pathways. *AMP (Adenosine monophosphate)* - AMP is also a purine nucleotide that requires **N10-formyl-THF** cofactors during de novo synthesis (same pathway branch point as GMP). - Like GMP, it is affected but **less directly than TMP**, and salvage pathways provide alternative synthesis routes. *UMP (Uridine monophosphate)* - UMP is synthesized through the **de novo pyrimidine pathway** which does not require folate cofactors. - Methotrexate does not inhibit the enzymes (carbamoyl phosphate synthetase II, aspartate transcarbamoylase, dihydroorotase, etc.) involved in UMP synthesis.
Practice by Chapter
Antiparasitic drugs (antiprotozoals)
Practice Questions
Antimalarial medications
Practice Questions
Anthelmintics
Practice Questions
Antiseptics and disinfectants
Practice Questions
Antimicrobial stewardship principles
Practice Questions
Empiric antimicrobial selection
Practice Questions
Antimicrobial dosing in special populations
Practice Questions
Antimicrobial pharmacokinetics/pharmacodynamics
Practice Questions
Antimicrobial toxicities
Practice Questions
Antimicrobial allergies and cross-reactivity
Practice Questions
Combination antimicrobial therapy
Practice Questions
Cost-effective antimicrobial strategies
Practice Questions
New antimicrobial development
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free